Bibliographic information

GuidelineMental Health Gap Action Programme (‎mhGAP)‎ guideline for mental, neurological and substance use disorders, [‎3rd ed.]‎.
Year of Publication2023
Issuing InstitutionWorld Health Organization

Recommendation

New

In adults with moderate-to-severe depression who have benefited from initial antidepressant treatment, continuation of the antidepressant treatment should be considered for at least six months after remission. Treatment should be regularly monitored, with special attention to treatment adherence, change in depressive symptoms and possible adverse effects

Recommended in favor

Conditional

Notes and Remarks

Remarks y The term “depression” refers to moderate-to-severe depressive episode or disorder. y The term “remission” is defined as relief from depressive symptoms. y The studies identified in the review included people experiencing first or recurrent episodes of depression. y Antidepressants are typically most effective in the initial 6–12 months and should only be continued where there is need and clinical oversight.

Implementation considerations y Long-term antidepressant use may be associated with additional adverse effects such as weight gain. y Specific types of antidepressants selected should carefully consider factors such as demographic characteristics (e.g. higher risks that may be associated with pregnancy or older age) and side-effects profiles (e.g. sexual dysfunction, sleep problems, weight gain). y When discontinuing antidepressants, abrupt discontinuation should be avoided and medicine doses should be tapered off slowly. Any withdrawal symptoms should be closely monitored. y Providers should keep in mind the possible adverse effects associated with antidepressants, the ability to deliver either intervention (in terms of expertise, and/or treatment availability) and individual preferences. Discontinuities in drug availability (common in LMICs) may interfere with continuation of treatment. y Costs accumulate with duration of prescription. Cost of daily dose of generic antidepressants varies from region to region throughout the world ranging between 3% and 9% of minimum wage (131).